OBIO Member, CCAB, has signed a collaboration and license agreement with Pionyr Immunotherapeutics Inc. to discover antibody drug development candidates. Through the University of Toronto, CCAB, has granted a non-exclusive license to Pionyr Immunotherapeutics encompassing an undisclosed number of antibody programs in Pionyr’s therapeutic pipeline.
Click HERE for the Full Press Release